恩替卡韦联合五灵胶囊治疗代偿期乙型肝炎肝硬化的效果  

Effect of entecavir combined with wuling capsules in the treatment of compensated hepatitis B cirrhosis

作　　者：刘加群[1] 曹立华[1] 鲁小杰 赵鸿[3] 王思宇 杨延源[1] 张继东[1] Liu Jiaqun;Cao Lihua;Lu Xiaojie;Zhao Hong;Wang Siyu;Yang Yanyuan;Zhang Jidong(Qinhuangdao Third Hospital,Qinhuangdao 066000,China;First Affiliated Hospital of Nanjing Medical University,Nanjing 210000,China;First Hospital of Peking University,Beijing 100000,China)

机构地区：[1]河北省秦皇岛市第三医院,066000 [2]南京医科大学附属第一医院,江苏省210000 [3]北京大学第一医院,100000

出　　处：《中国实用医刊》2021年第8期116-118,共3页Chinese Journal of Practical Medicine

摘　　要：目的探讨恩替卡韦联合五灵胶囊治疗代偿期乙型肝炎肝硬化的效果。方法抽取2018年1月至2020年7月秦皇岛市第三医院收治的代偿期乙型肝炎肝硬化患者90例,根据治疗方案将其分为对照组和观察组,每组45例。对照组给予恩替卡韦治疗,观察组给予恩替卡韦联合五灵胶囊治疗。回顾性比较两组肝功能指标、肝纤维化指标、乙型肝炎病毒核糖核酸(HBV-DNA)转阴率及不良反应。结果治疗后,观察组丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、总胆红素、透明质酸、层黏蛋白、Ⅲ型前胶原水平低于对照组(t=5.595、6.857、8.729、9.392、5.402、5.064,P<0.05)。治疗后,观察组HBV-DNA转阴率为82.22%(37/45),高于对照组的62.22%(28/45)。两组不良反应发生率比较,差异未见统计学意义(χ^(2)=0.104,P=0.748)。结论恩替卡韦联合五灵胶囊可有效抑制代偿期乙型肝炎肝硬化患者的肝纤维化,改善肝功能,增高HBV-DNA转阴率,且不增加不良反应。Objective To investigate the effect of entecavir combined with wuling capsule in the treatment of compensated hepatitis B Cirrhosis.Methods A total of 90 patients with compensatory hepatitis B cirrhosis who were admitted to Qinhuangdao Third Hospital from January 2018 to July 2020 were selected.According to the treatment plan,they were divided into control group and observation group,with 45 cases in each group.The control group was treated with entecavir,and the observation group was treated with entecavir combined with wuling capsules.The liver function indexes,liver fibrosis indexes,hepatitis B virus nucleic acid(HBV-DNA)conversion rate and adverse reactions were retrospectively compared between the two groups.Results After treatment,the levels of alanine aminotransferase,aspartate aminotransferase,total bilirubin,hyaluronic acid,laminin,and procollagenⅢin the observation group were lower than those in the control group(t=5.595,6.857,8.729,9.392,5.402,5.064,P<0.05).After treatment,the negative rate of HBV-DNA in the observation group was 82.22%(37/45),which was higher than 62.22%(28/45)in the control group.There was no significant difference in the incidence of adverse reactions between the two groups(χ^(2)=0.104,P=0.748).Conclusions Entecavir combined with wuling capsule can effectively inhibit liver fibrosis,improve liver function,increase HBVDNA negative rate,and do not increase adverse reaction.

关 键 词：乙型肝炎 肝硬化 代偿期 五灵胶囊 恩替卡韦 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]